In Silico Design of a Dual-Target Phenobarbital Analog for GABAₐ Modulation and SERT Inhibition to Reduce Depressive Side Effects

Dweny Geeth^1,2, Jin Jin¹ & Shaozhong Zhang¹

¹ Western Illinois University, Illinois, USA
² Illinois Mathematics and Science Academy

Abstract

Background/Objective: Phenobarbital, a barbiturate commonly used as an anticonvulsant, enhances GABA_ₐ receptor activity to suppress neuronal excitability. However, its clinical use is limited by central nervous system side effects, particularly depression. This study proposes structural modifications to the phenobarbital molecule aimed at reducing effects of depression while maintaining its anticonvulsant efficacy.
Methods: By adding functional groups that affect serotonin pathways, the modified compound is designed to reduce phenobarbital’s depressive effects. The introduction of a trifluoromethyl group is designed to improve blood–brain barrier permeability and metabolic stability. Additionally, incorporating an O–CH₂–CH₂–NH₂ group targets serotonin pathways to help mitigate depressive side effects while preserving anticonvulsant function. Utilizing pharmacophore and structural analysis, this proposal identifies potential chemical modifications that could enhance GABA selectivity and improve blood–brain barrier permeability. Molecular docking studies were performed using SwissDock to computationally validate the dual target binding hypothesis.
Results: A theoretical synthetic pathway was also developed for the proposed compound. Computational docking demonstrated that the analog exhibited favorable binding to both GABA_ₐ receptors (ΔG = –4.905 kcal/mol) and serotonin transporters (ΔG = −5.367 kcal/mol), with binding energies comparable to or exceeding phenobarbital at GABA_ₐ and approaching the affinity of selective serotonin reuptake inhibitors at SERT. After the drug is synthesized, future plans include conducting structure-activity relationship studies, binding assays, and in vivo testing to evaluate drug effects and metabolism.
Conclusions: While this research is theoretical and requires experimental validation, it presents a molecule that could potentially serve as a promising framework for optimizing existing anticonvulsant drugs while hypothetically reducing side effects of depression; experimental validation is required before any clinical conclusions can be drawn.

Keywords: phenobarbital, anticonvulsant, serotonin modulation, GABA_ₐ receptor, structure activity relationship

Introduction

Background and Context

Epilepsy affects approximately 50 million people worldwide, making it one of the most common neurological disorders globally¹. Anticonvulsant drugs have improved greatly since the early 1900s, with phenobarbital becoming one of the first effective seizure treatments¹. Phenobarbital has long been used as a treatment for many seizure disorders due to its effectiveness in enhancing GABA_ₐ receptor activity and reducing neuronal excitability¹. This occurs through the prolonged opening of chloride channels at GABA_ₐ receptors, resulting in increased chloride influx, neuronal hyperpolarization, and reduced excitability².

Barbiturates, the drug class that includes phenobarbital, played a key role in the history of seizure treatment¹. Despite the introduction of numerous newer antiepileptic drugs over the past decades, phenobarbital remains widely prescribed due to its proven efficacy, low cost, and availability in resource-limited settings³. Understanding how phenobarbital affects GABA_ₐ receptors has helped explain how the brain prevents seizures⁴.

Problem Statement and Rationale

Although it has proven effective, phenobarbital has many central nervous system (CNS) side effects, such as sedation, cognitive dulling, and depression^5,6. The side effects reduce patient quality of life, especially in individuals with underlying mood disorders⁵. While newer anticonvulsant drugs have been developed, they often come with their own drawbacks, including higher development and treatment costs².

It is important to recognize that the CNS side effects of phenobarbital, including depression, are multifactorial in nature. Depressive symptoms likely arise from a combination of direct GABAergic sedation, global reduction in brain excitability, interactions with multiple neurotransmitter systems, and—among these—limited engagement with mood-regulating pathways such as the serotonergic system^5,6. Sedation and fatigue represent distinct phenomena from mood disturbances, though they often co-occur. This study specifically targets the mood-related (serotonergic) component of phenobarbital’s depressive burden, and does not claim to address sedation or cognitive dulling, which may have separate mechanistic origins.

Recent studies suggest that these depressive symptoms may in part arise from phenobarbital’s limited interaction with neurotransmitter systems involved in mood regulation, such as serotonin¹This creates a large gap in current epilepsy treatment, because patients often choose between seizure control and mental health stability⁵. The existing research highlights a clear need for anticonvulsants that can provide control against seizures without negatively affecting mood⁵. This highlights a need to develop modified versions of phenobarbital that are effective as an anticonvulsant and reduce its depressive impact.

Significance and Purpose

This research addresses an important clinical need by potentially providing a solution that combines the proven anticonvulsant efficacy of phenobarbital with reduced psychiatric side effects⁵. The significance of this research could extend beyond individual patient care to broader public health effects, especially in low- and middle-income countries where phenobarbital is a primary treatment option due to cost considerations². Structural modification of drugs is a common approach in medicinal chemistry to enhance therapeutic effects while minimizing side effects⁷.

The development of an improved phenobarbital version could demonstrate how older medications can be improved through specific chemical modifications⁷This approach represents a cost-effective alternative to developing entirely new drug classes, potentially making improved epilepsy treatment more accessible globally².

Objectives

1. To preserve the barbituric acid pharmacophore that maintains anticonvulsant efficacy through GABAₐ receptor modulation⁴.
2. To incorporate functional groups that may minimize serotonin-related depressive effects while keeping the main function of an anticonvulsant⁸
3. To enhance blood–brain barrier permeability through addition of lipophilic groups³.
4. To develop a theoretically feasible synthesis pathway for the proposed analog compound⁶.
5. To computationally validate dual-target binding through molecular docking studies against GABAₐ receptors and serotonin transporters.

Scope and Limitations

This research is limited to theoretical drug design using computational molecular modeling, structural analyses⁷, and molecular docking studies. The study encompasses the rational design of molecular modifications, development of synthesis pathways, and structure-activity relationship analysis⁴. However, the scope does not include experimental synthesis, in vitro binding studies, pharmacokinetic analysis, or in vivo efficacy testing². Validating this model experimentally is potential future work but was beyond the study’s resource constraints and timeline.

The theoretical computational nature of this research means that all mechanisms and effects proposed will require experimental validation². Additionally, the study focuses specifically on phenobarbital modification rather than exploring other anticonvulsants or classes of drugs⁴.

Theoretical Framework

The design strategy is based on established structure-activity relationship (SAR) principles and polypharmacology approaches⁴. Polypharmacology refers to the deliberate design of a compound to modulate multiple biological targets simultaneously, which can provide additive or complementary therapeutic benefits⁴. Whether a dual-action approach is superior to highly selective agents depends on context; in this case, the hypothesis is that combining anticonvulsant and SSRI-like activity in one molecule could reduce pill burden for patients who require both. This remains to be validated experimentally.

The theoretical framework comes from two main areas: GABAergic neurotransmission theory for maintaining anticonvulsant activity, and serotonergic neurotransmission theory for addressing mood-related side effects⁷. Specifically, a trifluoromethyl group is proposed to improve lipophilicity and metabolic stability, while an O–CH₂–CH₂–NH₂ group is included to inhibit serotonin reuptake⁸. These represent distinct mechanisms: receptor mimicry targets a receptor agonist effect, whereas reuptake inhibition targets SERT to increase synaptic serotonin. This study adopts the SERT inhibition hypothesis exclusively; language suggesting receptor mimicry has been removed throughout this revision.

The framework also incorporates principles from selective serotonin reuptake inhibitor (SSRI) design to address the mood-related complications associated with phenobarbital use⁹. It should be noted that the 2-aminoethoxy group is a design probe with structural inspiration from serotonin’s ethylamine side chain, and does not constitute a confirmed SSRI motif. Its SERT binding capability requires validation through docking and experimental assays.

Methods

Research Design

This study used computational molecular modeling to create a theoretical drug design. The research design was descriptive, focusing on rational modification of phenobarbital through the development of a synthesis pathway and the analysis of SAR, and computational validation through molecular docking.

Data Collection

Before the modified compound and synthesis pathway were designed, preliminary research was conducted to determine which molecules would be most effective in combatting the depressive effects of phenobarbital and enhancing uptake of phenobarbital, while also acting as an anticonvulsant. Additionally, the molecular structures of serotonin and SSRIs such as fluoxetine and vilazodone were analyzed⁹. King Draw’s KDpedia search engine was used to ensure that a novel compound would be designed.

Variables and Measurements

The modified compound and synthesis pathway were designed using ChemDraw and MolView. In order to preserve the compound’s pharmacophore while inhibiting the reuptake of serotonin and increasing the absorption of the drug, the barbituric acid ring was not altered⁴. A trifluoromethyl (–CF₃) group was added at the para-position of the ring to increase lipophilicity and promote blood–brain barrier permeability³. A 2-aminoethoxy (–O–CH₂–CH₂–NH₂) groups.

A 2-aminoethoxy (–O–CH₂–CH₂–NH₂) group was introduced at the meta-position due to its function in modulating serotonergic activity⁹. The para-position was selected for the –CF₃ group because para-substitution avoids steric interference with the barbituric acid core’s key binding interactions and is a commonly used position for lipophilicity-enhancing fluorine substituents in CNS drug design³. The meta-position was chosen for the –O–CH₂–CH₂–NH₂ group to provide spatial separation from the –CF₃ group while allowing the amine terminus to project toward the serotonin transporter binding pocket. The 2-carbon spacer was selected based on structural analogy to the ethylamine side chain of serotonin; future work should explore 3-carbon and 4-carbon chain variants to establish structure-activity relationships for this substituent.

Some of the key variables were the preservation of the pharmacophore, enhancement of lipophilicity through the trifluoromethyl group, and modulation of serotonin with the addition of the aminoethoxy group.

Procedure

Molecular Design

After preliminary research was conducted, the trifluoromethyl and aminoethoxy groups were added to phenobarbital. The synthesis pathway was conceptualized to include two alkylation steps (discussed below), followed by a final condensation reaction to synthesize the final molecule¹⁰. The synthesis pathway of the phenobarbital analog was modeled after the established phenobarbital synthesis pathways described in the literature¹¹. The procedure involved multiple analyses of all steps of the reaction to ensure accuracy and maintained synthetic feasibility. The synthesis pathway was modeled in MolView and ChemDraw.

Precursor Availability

The proposed synthesis assumes the use of a substituted aryl iodide bearing both the –CF₃ group at the para-position and the –O–CH₂–CH₂–NH₂ group at the meta-position as a starting material. If this precursor is not commercially available (which is likely), a short precursor synthesis would be required. A plausible route would begin from a commercially available meta-amino-para-fluorobenzene scaffold: (1) introduction of the aminoethoxy chain via O-alkylation of a phenol precursor with N-protected 2-bromoethylamine, (2) Boc deprotection to reveal the free amine, (3) Balz–Schiemann reaction or Halex fluorination to install –CF₃, and (4) iodination at the appropriate position. This precursor synthesis should be developed and included in future full experimental protocols.

Synthesis Steps

Step 1 (First Alkylation): The first step of the synthesis involves an α-arylation of diethyl malonate with the substituted aryl iodide, performed under palladium catalysis (Pd-catalyzed Buchwald-type conditions). The recommended conditions are: Pd₂(dba)₃ (2 mol%), a phosphine ligand (e.g., BINAP or DavePhos), and a non-hydrolyzing base such as Cs₂CO₃ or K₃PO₄ in toluene or dioxane at 80–100 °C.

Step 2 (Second Alkylation): In the second step, an O-alkylation/C-alkylation is performed to install the ethyl group. Recommended conditions use sodium ethoxide (NaOEt) in dry ethanol as the base, reacting with ethyl bromide at 0 °C to room temperature. NaOEt is preferred over NaOH here because it is a strong, non-nucleophilic base that deprotonates the malonate α-carbon without causing ester hydrolysis. Conditions: NaOEt (1.1 equiv.), EtBr (1.1 equiv.), ethanol, 0 °C to r.t., 2–4 h.

Step 3 (Condensation): The final step of the synthesis pathway is a condensation reaction in which the product formed in the second reaction reacts with urea to form the phenobarbital analog. The phenobarbital analog synthesis pathway was modeled after the phenobarbital synthesis pathway¹¹.

Molecular Docking Studies

To computationally validate the dual-target binding hypothesis, molecular docking was performed using the SwissDock web server. Two protein targets were selected: the human GABA_ₐ receptor (PDB: 8bhg, α5/γ2 heteromer co-crystallized with bretazenil at 2.39 Å resolution) and the human serotonin transporter (PDB: 5i73, co-crystallized with S-citalopram at 3.15 Å resolution). These structures were chosen because they contain known modulators bound at the relevant pharmacological sites, providing clear binding pocket references. 20 parameters were chosen when docking 8bhg and 5i73, since those were the maximum amount of parameters allowed by SwissDock for both targets. For the GABA_ₐ  receptor α5 heteromer (PDB: 8BHG), antibody fragments, glycans, lipids, co‑crystallized ligands, ions, and all other heteroatoms were removed; only the protein coordinates were retained. For SERT docking (PDB: 5I73), antibody fragments, glycans, lipids, and co-crystallized ligands were removed. Physiologically relevant sodium ions were retained.

Ligands prepared for docking: (1) Phenobarbital (positive control for GABA_ₐ binding), (2) the proposed phenobarbital analog, (3) Vilazodone (positive control for SERT binding, a known SSRI), (4) Bretazenil (validation control for GABA_ₐ, should reproduce crystallographic pose). 5) Fluoxetine (positive control for SERT binding, a known SSRI. Ligand structures were generated as canonical SMILES strings and converted to 3D conformations by SwissDock. Unbiased docking searches were performed across the entire protein surface. The docking parameter RIC was set to 8 for comprehensive conformational sampling. Binding affinities were evaluated based on predicted Gibbs free energy (ΔG, kcal/mol). Binding poses were analyzed using PLIP (Protein-Ligand Interaction Profiler).

Data Analysis

This methodology aimed to retain phenobarbital’s anticonvulsant properties while inhibiting serotonin reuptake, inspired by SSRIs like fluoxetine and vilazodone⁹. Qualitative structural analysis was conducted to compare the modified compound against existing medicinal chemistry principles⁶. This included assessment of pharmacophore preservation, evaluation of synthetic feasibility, and analysis of functional group compatibility⁸. Docking results were compared across ligands and targets to assess whether the analog maintained GABA_ₐ binding affinity while gaining SERT interaction capability relative to phenobarbital.

Results

Molecular Design Outcomes

The design of the modified phenobarbital analog incorporated a trifluoromethyl group at the para position and a 2-aminoethoxy group at the meta position, modeled in ChemDraw and MolView. The barbituric acid core, essential for GABAergic modulation and seizure control, was fully preserved⁴. The rationale for these specific positions and the 2-carbon chain length is detailed in the Variables and Measurements section above.

Property	Phenobarbital	Proposed Analog	CNS-Favorable Threshold
Molecular Weight (Da)	232.2	~350.4 (estimate)	< 500
logP	~1.4	~2.8 (estimate, CF₃ adds +1.0; –O–CH₂CH₂NH₂ subtracts ~0.6)	1–5 (CNS: ideally 1–3)
Polar Surface Area (PSA, Ų)	~75	~110 (estimate; amine + ether add PSA)	< 90 Ų for CNS
H-bond Donors (HBD)	2 (NH×2)	3 (NH×2 + NH₂)	< 3
H-bond Acceptors (HBA)	3	5	< 7
Predicted pKa of –NH₂	N/A	~9.5 (primary amine)	See note below
Predicted Ionization at pH 7.4	N/A	~95% protonated (NH₃⁺)	Reduces BBB crossing

GABAₐ Receptor Binding

Docking studies with the GABA_ₐ receptor (PDB: 8bhg) demonstrated that the phenobarbital analog exhibited favorable binding affinity. The analog achieved an average binding energy of ΔG = -4.905 kcal/mol, which was superior to phenobarbital’s average binding energy of ΔG = -4.47 kcal/mol. Bretazenil docked with ΔG = –5.218 kcal/mol and successfully reproduced the crystallographic binding pose, validating the docking methodology.

Compound	Best ΔG (kcal/mol)	Worst (kcal/mol)	Average ΔG (kcal/mol)	Binding Site	Key Interactions
Phenobarbital	−4.979 kcal/mol	−3.248  kcal/mol	−4.47 kcal/mol	Benzodiazepine/ barbiturate site	Hydrogen bonds: Ser275A, Asn278A, Ser285B Hydrophobic contacts: Thr271E, Leu272A, Ile274A, Ile274B π–π / π-stacking interactions: Phe68, Tyr213
Phenobarbital analog	–5.260 kcal/mol	–4.436 kcal/mol	–4.905 kcal/mol	Benzodiazepine/barbiturate site	Hydrogen bonds: Asn278A, Ser285B, Ser286B Hydrophobic contacts: Leu274A, Ile281B, Thr270C π–π / π-stacking interactions: Phe68, Tyr213
Bretazenil (validation)	–5.779 kcal/mol	–4.837 kcal/mol	–5.218 kcal/mol	Crystallographic site	Hydrogen bonds: Thr133D, Thr142B Hydrophobic contacts: Tyr213D, Phe68D, Thr210E π–π / π-stacking interactions: Phe68D, Tyr213E

Serotonin Transporter Binding

Docking to the serotonin transporter (PDB: 5i73) revealed that the phenobarbital analog demonstrated enhanced SERT binding compared to phenobarbital. The analog achieved an average binding energy of ΔG = −5.367 kcal/mol, representing a 0.689 kcal/mol improvement over phenobarbital (average binding energy of ΔG = −4.678 kcal/mol). While the analog did not achieve the binding affinity of vilazodone (ΔG = −6.453 kcal/mol), a clinically used SSRI, it approached this benchmark, suggesting meaningful SERT interaction capability.

Compound	Best ΔG (kcal/mol)	Worst (kcal/mol)	Average ΔG (kcal/mol)	Binding Site	Key Interactions
Phenobarbital	-5.348 kcal/mol	-4.182 kcal/mol	−4.678  kcal/mol	Benzodiazepine/ barbiturate site	Hydrogen bonds: Thr497A, Asp247A Hydrophobic contacts: Ile172A, Phe341A, Ala331A, Leu502A, Ile552A π–π / π-stacking interactions: Phe335A Salt bridges: Asp98A with Tertamine moiety of ligand
Phenobarbital analog	–6.183 kcal/mol	–4.775 kcal/mol	−5.367  kcal/mol	Benzodiazepine/ barbiturate site	Hydrogen bonds: Thr497A, Asp247A (similar to phenobarbital, main H-bonds in pocket) Hydrophobic contacts: Ile172A, Phe341A, Ala331A, Leu502A, Ile552A (residues lining the pocket) π–π / π-stacking interactions: Phe335A (aromatic stacking) Salt bridges / cation–π: Glu494A, Asp98A
Vilazodone (SSRI control)	-7.067 kcal/mol	-6.018 kcal/mol	−6.453 kcal/mol	Crystallographic site	Hydrogen bonds: Ser438A, Asn101A Hydrophobic contacts: Ile172A, Phe341A, Leu502A π–π / π-stacking interactions: Phe335A Salt bridges: Glu494A with Tertamine moiety
Fluoxetine (SSRI control)	-6.141 kcal/mol	-5.150 kcal/mol	-5.598 kcal/mol	SERT central binding pocket (S1 site)	Hydrogen bonds: Ser438A Hydrophobic contacts: Ile172A, Phe341A, Leu502A, Ile552A π–π / π-stacking interactions: Phe335A Salt bridges: Glu494A (if protonated amino group interacts)

Discussion

Restatement of Key Findings

This project aimed to design a phenobarbital analog that could retain anticonvulsant activity while reducing depressive side effects. The analog preserved the barbituric acid core, the pharmacophore⁴. Two functional groups were added to address blood–brain barrier permeability and serotonergic activity: a para-position trifluoromethyl and a meta-position 2-aminoethoxy group³. Computational docking studies provided evidence supporting the dual-target hypothesis, demonstrating that the analog maintains favorable GABA_ₐ receptor binding while gaining enhanced serotonin transporter affinity compared to phenobarbital.

Computational Validation of Dual-Target Activity

Preserved GABAₐ Receptor Binding

The docking results confirmed that the phenobarbital analog retains strong binding affinity to the GABA_ₐ receptor. The barbituric acid pharmacophore docked in the same orientation as phenobarbital within the benzodiazepine/barbiturate binding site of the α5/γ2 GABA_ₐ receptor subtype. PLIP analysis confirmed that the analog maintained the essential hydrogen bonding and hydrophobic interactions characteristic of barbiturate binding at this site.

Enhanced Serotonin Transporter Interaction

The most significant finding from the docking studies is the analog’s enhanced affinity for SERT compared to phenobarbital. PLIP analysis confirmed that the 2-aminoethoxy substituent engages in favorable interactions with residues critical for serotonin and SSRI binding. The analog’s binding pose within the central substrate-binding site of SERT overlaps substantially with the binding modes of established SSRIs, suggesting that it could competitively inhibit serotonin reuptake.

Rationale for Structural Modifications

Trifluoromethyl Group

The trifluoromethyl substituent was chosen for its electron-withdrawing properties and high lipid solubility, potentially improving central nervous system penetration³.

However, an important pharmacokinetic trade-off must be acknowledged: while –CF₃ improves lipophilicity and BBB penetration, the co-present primary amine (–NH₂) of the 2-aminoethoxy group has a predicted pKa of approximately 9.5. At physiological pH 7.4, this amine will be approximately 95% protonated (–NH₃⁺), substantially increasing polarity and reducing passive BBB permeability. This ionic form may also make the compound a substrate for P-glycoprotein (P-gp) efflux transporters, further limiting CNS exposure. To address this, future work should: (1) predict logD at pH 7.4 and polar surface area using validated in silico tools (SwissADME, ChemAxon); (2) evaluate CNS penetration using PAMPA-BBB or MDCK-MDR1 assays; and (3) consider a prodrug strategy in which the amine is masked as a carbamate (Boc or Cbz analogue) or converted to a less basic group (e.g., sulfonamide, amide) to improve BBB crossing while retaining SERT binding capability³.

2-Aminoethoxy Group

The 2-aminoethoxy group, structurally inspired by serotonin’s ethylamine side chain, was designed to support potential interaction with the serotonin transporter^9,11. It should be emphasized that this group is a design probe—not a confirmed SSRI motif. SSRIs such as fluoxetine and sertraline have highly specific scaffold geometries and pharmacophore spacing optimized over many iterative design cycles; the 2-aminoethoxy group alone does not recapitulate this. The expected outcome of SERT interaction, if confirmed, would be increased synaptic serotonin availability (similar to SSRI mechanism), not receptor agonism.

Steric Considerations

An important limitation is the potential for steric hindrance introduced by the para-–CF₃ and meta-–O–CH₂–CH₂–NH₂ substituents on the phenyl ring. Although the barbituric acid core was preserved, the bulkier substituted phenyl ring may alter the compound’s fit within the GABA_ₐ binding pocket. The docking overlay of phenobarbital vs. the analog should be examined for steric clashes or pocket-wall collisions. If the docking results reveal unfavorable steric interactions, this would constitute a significant limitation and the substituent positions or sizes should be reconsidered.

Clinical and Therapeutic Significance

This theoretical design addresses the significant clinical need in epilepsy treatment by potentially limiting one of phenobarbital’s most serious side effects while maintaining its effectiveness as an anticonvulsant¹³. This approach aligns with modern medicinal chemistry strategies that explore polypharmacology—developing compounds that act on multiple biological pathways^4,14,15. The concept of dual-target engagement has been successfully applied in CNS drug development, for example in the design of compounds with combined antidepressant and anxiolytic activity¹².

Future Directions and Recommendations

Proposed Future Validation Subsection

A structured validation plan is proposed, in order of priority¹⁶:

1. Computational docking (already initiated): Complete SwissDock docking and PLIP analysis with actual ΔG values; perform steric overlay of phenobarbital vs. analog in GABAₐ pocket; compute SwissADME/logD/PSA predictions. Compare against decoy compounds.
2. Experimental synthesis: Synthesize the analog using the corrected 3-step route (Pd-catalyzed arylation → NaOEt alkylation → urea condensation). Characterize by ¹H NMR, ¹³C NMR, HRMS.
3. In vitro binding assays: [³H]muscimol displacement assay for GABAₐ binding; [³H]citalopram displacement assay for SERT binding. Controls: phenobarbital (GABAₐ), bretazenil, fluoxetine (SERT), vilazodone (SERT)¹⁷.
4. In vivo studies: Test in standard seizure models (maximal electroshock, PTZ-induced seizures). Assess mood effects using forced swim test, tail suspension test, sucrose preference test. Compare to phenobarbital and a standard SSRI control. Include control groups^18,19,20.
5. Safety and toxicology: Assess cytotoxicity, CYP450 inhibition, and hERG liability before advancing to preclinical development.

Limitations

The most significant limitation of this study is its reliance on computational predictions rather than experimental data—every proposed mechanism and effect requires experimental validation before meaningful clinical conclusions can be drawn^21,22. The synthesis pathway builds on well-established organic chemistry principles, but real-world laboratory conditions often present unexpected challenges^10,23. Perhaps most importantly, the assumption that structural similarity to serotonin will translate into beneficial mood effects remains unproven without proper binding studies and functional assays.

The computational modeling approach lacks the sophistication of advanced techniques like quantum mechanical calculations or molecular dynamics simulations^24,25. Complex metabolic pathways that could transform this compound in the body have not been considered. The protonation of the primary amine at physiological pH represents a significant but addressable limitation for BBB penetration (see Trifluoromethyl Group discussion above). The study’s focus on depression as the primary side effect may also overlook sedation and cognitive dulling, which are not addressed by the serotonergic modification.

Closing Thought

This project demonstrated the conceptual design of a phenobarbital analog that potentially preserve anticonvulsant effects while hypothetically reducing the serotonergic component of depressive side effects, pending experimental validation²². By retaining the barbituric acid core and integrating functional groups targeting blood–brain barrier permeability and serotonergic activity, the analog aligns with emerging strategies in psychopharmacology⁴. While experimental validation remains a future goal, the proposed synthesis pathway and reasoning behind structural modifications provide a basis for continued progress^21,26,25.

References

1. D. M. Treiman, et al. A Comparison of Four Treatments for Generalized Convulsive Status Epilepticus. New England Journal of Medicine, 339(12), 792–798, 17 Sept. 1998, https://doi.org/10.1056/nejm199809173391202. [↩] [↩] [↩] [↩] [↩]
2. T. Takebe, et al. The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development. Clinical and Translational Science, 11(6), 597–606, 30 July 2018, https://doi.org/10.1111/cts.12577. [↩] [↩] [↩] [↩] [↩] [↩]
3. L. Wang, et al. Design, Synthesis, and Activity Evaluation of Fluorine-Containing Scopolamine Analogues as Potential Antidepressants. Journal of Medicinal Chemistry, 67(7), 5391–5420, 14 Feb. 2024, https://doi.org/10.1021/acs.jmedchem.3c01970. [↩] [↩] [↩] [↩] [↩] [↩] [↩]
4. H. Zhu, et al. A Pharmacophore-Guided Deep Learning Approach for Bioactive Molecular Generation. Nature Communications, 14(1), 6234, 6 Oct. 2023, https://doi.org/10.1038/s41467-023-41454-9. [↩] [↩] [↩] [↩] [↩] [↩] [↩] [↩] [↩] [↩] [↩]
5. D. A. Brent, P. K. Crumrine, R. Varma, R. V. Brown, M. J. Allan. Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics, 85(6), 1086–1091, 1990. [↩] [↩] [↩] [↩] [↩] [↩]
6. V. J. Jaramillo, et al. Does phenobarbital reduce hospital length of stay for alcohol withdrawal? JAPhA Pharmacotherapy, 1(1), 100003, 2024. [↩] [↩] [↩] [↩]
7. J. Li, et al. Innovative Synthesis of Drug-like Molecules Using Tetrazole as Core Building Blocks. Beilstein Journal of Organic Chemistry, 20, 950–958, 29 Apr. 2024, https://doi.org/10.3762/bjoc.20.85. [↩] [↩] [↩] [↩]
8. S. Manepalli, et al. Discovery of Novel Selective Serotonin Reuptake Inhibitors through Development of a Protein-Based Pharmacophore. Journal of Chemical Information and Modeling, 51(9), 2417–2426, 26 Sept. 2011, https://doi.org/10.1021/ci200280m. [↩] [↩] [↩]
9. L. Boschloo, et al. The Complex Clinical Response to Selective Serotonin Reuptake Inhibitors in Depression: A Network Perspective. Translational Psychiatry, 13(1), 1–7, 21 Jan. 2023, https://doi.org/10.1038/s41398-022-02285-2. [↩] [↩] [↩] [↩] [↩]
10. J. Li, et al. Innovative Synthesis of Drug-like Molecules Using Tetrazole as Core Building Blocks. Beilstein Journal of Organic Chemistry, 20, 950–958, 29 Apr. 2024, https://doi.org/10.3762/bjoc.20.85. [↩] [↩]
11. J. Michely, et al. A Mechanistic Account of Serotonin’s Impact on Mood. Nature Communications, 11(1), 11 May 2020, https://doi.org/10.1038/s41467-020-16090-2. [↩] [↩] [↩]
12. A. Sitovs, V. Mohylyuk. Ex Vivo Permeability Study of Poorly Soluble Drugs across Gastrointestinal Membranes: Acceptor Compartment Media Composition. Drug Discovery Today, 29(12), 104214, 18 Oct. 2024, https://doi.org/10.1016/j.drudis.2024.104214. [↩] [↩]
13. Sara Stallworth et al. Evaluation of Phenobarbital Dosing Strategies for Hospitalized Patients with Alcohol Withdrawal Syndrome. General Hospital Psychiatry, vol. 85, 2023, pp. 155–162. https://doi.org/10.1016/j.genhosppsych.2023.10.014. [↩]
14. A. Sitovs, V. Mohylyuk. Ex Vivo Permeability Study of Poorly Soluble Drugs across Gastrointestinal Membranes: Acceptor Compartment Media Composition. Drug Discovery Today, 29(12), 104214, 18 Oct. 2024, https://doi.org/10.1016/j.drudis.2024.104214. [↩]
15. Andrejs Sitovs, Valentyn Mohylyuk. Ex Vivo Permeability Study of Poorly Soluble Drugs across Gastrointestinal Membranes: Acceptor Compartment Media Composition. Drug Discovery Today, vol. 29, no. 12, 2024, p. 104214. https://doi.org/10.1016/j.drudis.2024.104214. [↩]
16. Vaishali Sahasrabudhe et al. Impact of Model-Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost. Clinical Pharmacology & Therapeutics, 2025. https://doi.org/10.1002/cpt.3636. [↩]
17. Kevin G. Bath, Helen E. Scharfman. Impact of Early Life Exposure to Antiepileptic Drugs on Neurobehavioral Outcomes Based on Laboratory Animal and Clinical Research. Epilepsy & Behavior, vol. 26, no. 3, 2013, pp. 427–439. https://doi.org/10.1016/j.yebeh.2012.10.031. [↩]
18. A. Daina, O. Michielin, V. Zoete. SwissADME: a free web tool to evaluate pharmacokinetics. Scientific Reports, vol. 7, 2017, 42717. [↩]
19. P. Ertl, B. Rohde, P. Selzer. Fast calculation of molecular polar surface area as a sum of fragment-based contributions. Journal of Medicinal Chemistry, vol. 43, no. 20, 2000, pp. 3714–3717. [↩]
20. Juan Tamargo et al. Narrow Therapeutic Index Drugs: A Clinical Pharmacological Consideration to Flecainide. European Journal of Clinical Pharmacology, vol. 71, no. 5, 2015, pp. 549–567. https://doi.org/10.1007/s00228-015-1832-0. [↩]
21. T. Takebe, et al. The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development. Clinical and Translational Science, 11(6), 597–606, 30 July 2018, https://doi.org/10.1111/cts.12577. [↩] [↩]
22. Yvonne M. Hart, Simon D. Shorvon. The Nature of Epilepsy in the General Population I: Characteristics of Patients Receiving Medication for Epilepsy. Epilepsy Research, vol. 21, no. 1, 1995, pp. 43–49. https://doi.org/10.1016/0920-1211(95)00007-w. [↩] [↩]
23. Jordi Mestres et al. Ligand-Based Approach to in Silico Pharmacology: Nuclear Receptor Profiling. Journal of Chemical Information and Modeling, vol. 46, no. 6, 2006, pp. 2725–2736. https://doi.org/10.1021/ci600300k. [↩]
24. S. Manepalli, et al. Discovery of Novel Selective Serotonin Reuptake Inhibitors through Development of a Protein-Based Pharmacophore. Journal of Chemical Information and Modeling, 51(9), 2417–2426, 26 Sept. 2011, https://doi.org/10.1021/ci200280m. [↩]
25. Aylin Sertkaya et al. Costs of Drug Development and Research and Development Intensity in the US, 2000–2018. JAMA Network Open, vol. 7, no. 6, 2024. https://doi.org/10.1001/jamanetworkopen.2024.15445. [↩] [↩]
26. Vaishali Sahasrabudhe et al. Impact of Model-Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost. Clinical Pharmacology & Therapeutics, 2025. https://doi.org/10.1002/cpt.3636. [↩]